Canary Biologics is a trusted distributor of dehydrated amniotic ocular grafts, precision instruments, and comprehensive practice management solutions—purpose-built for ophthalmology and optometry practices committed to clinical excellence.
From biological grafts to surgical instruments, every product in our portfolio is selected to meet the rigorous demands of ophthalmic clinical practice.
Our flagship dehydrated amniotic ocular grafts provide a biologic scaffold rich in growth factors and cytokines, supporting corneal and conjunctival wound healing with proven clinical efficacy.
Section 361 HCT/PIndicated for a broad range of ocular surface conditions including pterygium repair, dry eye disease, chemical burns, corneal ulcers, and post-surgical conjunctival defects.
Multi-IndicationAvailable in multiple sizes and configurations — including self-retaining formats — that simplify intraoperative handling and reduce procedural time without compromising graft integrity.
Surgeon-OptimizedDehydrated technology allows ambient room-temperature storage with an extended shelf life — eliminating the need for specialized freezer equipment and simplifying in-office inventory management.
Ambient StoragePurpose-designed applicators that enable accurate, atraumatic placement of amniotic membrane grafts. Engineered for ergonomic control and consistent deployment across varied surgical field geometries.
Graft-CompatibleA curated selection of lid specula in multiple sizes and styles to support comfortable patient positioning and optimal surgical field exposure during ocular surface procedures.
Procedure-ReadyWe work directly with providers to source specialty instruments not found in standard catalogs. Our team can fulfill specific requests and facilitate custom configurations for specialized techniques.
Custom Orders WelcomeBeyond product distribution, Canary Biologics partners with your practice to support compliant operations and help your team deploy amniotic membrane therapy with confidence.
Supports the management of various ocular surface diseases and associated symptomology.
Our specialists support your team through the coding and billing process for amniotic membrane procedures — including appropriate CPT and HCPCS codes — to help ensure accurate and compliant claims submission.
We provide virtual training sessions for clinical and administrative staff, covering proper graft handling, patient education, and documentation requirements for compliance.
Ready to launch your ocular aesthetics offering but not sure where to begin? Request a consultation and our team will guide you through seamless IPL integration.
Every product we distribute meets rigorous regulatory and clinical standards. We only represent technologies we believe in and stand behind.
Our approach is guided by what enables clinicians and their teams to deliver consistent, high-quality patient care—from product selection to practice support.
We build long-term relationships grounded in clarity, trust, and mutual success.
Canary Biologics was founded on a simple premise: ophthalmologists deserve a distribution partner that understands the clinical, operational, and business dimensions of their practice — not just a vendor that ships product.
We specialize in dehydrated amniotic ocular grafts because the science is compelling, the outcomes are meaningful, and adoption within ophthalmic clinical practice continues to grow. We distribute only what we fully understand — and we ensure every provider we work with has the knowledge, instruments, and support to deploy these therapies confidently.
Our team brings together backgrounds in clinical care, ophthalmology, medical billing, and practice operations. When you partner with Canary Biologics, you gain access to that collective expertise — not just a product catalog.
"Our mission is to help ophthalmologists achieve better patient outcomes and healthier practices — through the right products, the right support, and the right partnership."
A curated overview of the science behind dehydrated amniotic membrane therapy, including clinical indications, key benefits, and peer-reviewed publications.
Dehydrated amniotic membrane (dAM) is a biologically derived tissue graft sourced from the innermost layer of the placenta — the amnion — which is harvested under strict aseptic conditions and processed through a dehydration and sterilization protocol that allows ambient-temperature storage. The membrane is composed of three layers: an epithelial surface, a basement membrane rich in extracellular matrix proteins, and an avascular stromal layer. This unique architecture provides a scaffold for corneal and conjunctival epithelial cell migration and regeneration.
Unlike cryopreserved formats, dehydrated amniotic membrane retains essential growth factors, cytokines, and matrix proteins that confer its anti-inflammatory, anti-fibrotic, and pro-regenerative properties — making it well-suited for a range of in-office and surgical ocular surface applications.
Dehydrated amniotic ocular membrane grafts have demonstrated clinical utility across a broad spectrum of ocular surface conditions, including persistent epithelial defects, neurotrophic corneal ulcers, dry eye disease (moderate-to-severe), chemical and thermal burns, pterygium repair and conjunctival reconstruction, post-surgical corneal surface defects, toxic and infectious keratopathy, and bullous keratopathy.
Published evidence highlights several consistent benefits of dAM use in ophthalmology: promotion of corneal re-epithelialization, reduction of patient-reported pain and discomfort, anti-inflammatory modulation of the ocular surface environment, minimally invasive sutureless application formats suitable for office-based procedures, and extended shelf life without specialized cold-storage requirements.
A retrospective study of 56 eyes across multiple ocular surface conditions treated with sutureless dehydrated amniotic membrane and bandage contact lenses. Demonstrated complete corneal re-epithelialization in the majority of cases, with significant reductions in patient pain scores. Authors conclude that the approach is minimally invasive and broadly applicable across a range of ocular surface disorders.
View on PubMedA prospective study enrolling 35 patients with moderate-to-severe dry eye disease (OSDI >30) who received bilateral sutureless dehydrated amniotic membrane under a specialized bandage contact lens. Assessments at baseline, 30-day control, and 30-day post-treatment demonstrated improvements in ocular surface signs and symptoms, supporting dAM as an effective in-office treatment option for refractory dry eye.
View on PubMedThis publication explores current evidence and emerging clinical applications of amniotic membrane transplantation in ophthalmology, including updated data on outcomes in ocular surface reconstruction, anti-inflammatory mechanisms, and evolving formats for clinical delivery. Please visit PubMed for the full abstract and citation details.
View on PubMedWhether you're evaluating amniotic membrane therapy for your practice or ready to place your first order, our team is here to help.
(855) 422-6246
Monday – Friday, 8am – 6pm EST
info@canarybiologics.com
We respond within one business day.
Mebane, North Carolina
United States